Xenia Venture Capital

Xenia Venture Capital is an Israeli high-tech and life sciences investment company founded in 2003 and publicly traded on the Tel Aviv Stock Exchange. Headquartered in Tel Aviv, Xenia invests in early-stage Israeli companies across high-tech and medical technology, with an increasing focus on life sciences. A core element of its platform is a 50% stake in VLX, a technological incubator operating under the Israel Innovation Authority's incubator program that supports data-driven biotech, pharma and digital-pharma startups. Beyond capital, Xenia provides portfolio companies with mentoring, business and strategic counseling, fundraising assistance, exit planning, and shared back-office infrastructure, finance, accounting, logistics and office support, services well suited to first-time scientific founders coming out of academia or the Israeli Innovation Authority incubator pipeline, and it generally invests as a co-investor. Since inception the firm has invested in more than 40 companies and notched one IPO and at least six acquisitions; flagship outcomes include the June 2020 NASDAQ IPO of PolyPid at roughly a $273M market cap, the acquisition of orthopedic device company OrthoSpace by Stryker, and the 2021 exit of MEC software vendor Saguna. Recent activity remains steady, with its most recent reported investment on April 8, 2025 in Arcuro Medical in surgical devices. The firm's leadership has included CEO Lars Thoren and previously Eli Sorzon, and the team comprises roughly eight people including seven partners. By pairing capital with incubation and back-office support, Xenia Venture Capital backs early-stage Israeli high-tech and life-sciences founders.